CN114720689B - 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用 - Google Patents

半夏凝集素蛋白酶联免疫Elisa试剂盒及应用 Download PDF

Info

Publication number
CN114720689B
CN114720689B CN202210362218.6A CN202210362218A CN114720689B CN 114720689 B CN114720689 B CN 114720689B CN 202210362218 A CN202210362218 A CN 202210362218A CN 114720689 B CN114720689 B CN 114720689B
Authority
CN
China
Prior art keywords
ser
thr
val
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210362218.6A
Other languages
English (en)
Other versions
CN114720689A (zh
Inventor
郁红礼
吴皓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing University of Chinese Medicine
Original Assignee
Nanjing University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing University of Chinese Medicine filed Critical Nanjing University of Chinese Medicine
Priority to CN202210362218.6A priority Critical patent/CN114720689B/zh
Publication of CN114720689A publication Critical patent/CN114720689A/zh
Priority to PCT/CN2022/109669 priority patent/WO2023193376A1/zh
Application granted granted Critical
Publication of CN114720689B publication Critical patent/CN114720689B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42Lectins, e.g. concanavalin, phytohaemagglutinin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

半夏凝集素蛋白酶联免疫Elisa试剂盒及应用,属于生物技术领域,该试剂盒含有单克隆抗体25E2E8和/或单克隆抗体28E3D3,所述25E2E8抗体重链的氨基酸序列如SEQ ID NO:4所示,轻链的氨基酸序列如SEQ ID NO:8所示;所述28E3D3抗体重链的氨基酸序列如SEQ ID NO:14所示,28E3D3抗体轻链的氨基酸序列如SEQ ID NO:18所示。本发明试剂盒由PTL的单克隆抗体制备而成,可以达到快速且灵敏地定量检测样品中半夏凝集素蛋白含量。

Description

半夏凝集素蛋白酶联免疫Elisa试剂盒及应用
技术领域
本发明属于生物技术领域,具体涉及半夏凝集素蛋白酶联免疫Elisa试剂盒及应用。
背景技术
半夏凝集素蛋白(Pinellia ternate lectin,PTL)属于植物凝集素中的单子叶植物甘露糖结合凝集素蛋白。PTL为氨基酸序列长度为256-258aa,分子量为25-27kDa,等电点为6-7的植物蛋白,具有抗虫、抗真菌、抗肿瘤以及凝血的作用。PTL由天南星科植物半夏的鲜品经过提取纯化得到。
目前某种特定蛋白含量的检测方法常采用Western Blot(免疫印迹)法或ELISA(酶联免疫吸附测定)法。其中Western Blot法过程较为繁琐、耗时长,成本较高、检测线性范围窄,且此法属于半定量方法,多用于两种样品中某种蛋白含量的比较。本发明所述PTL检测试剂盒是以PTL的单克隆抗体为原料制备的ELISA试剂盒,可以用于样品中PTL的定量检测,方法灵敏度高、重复性、特异性好,简便、快速,成本较低,可同时进行大批量样品测定。 同时本发明提供的用于制备ELISA试剂盒的抗体为PTL的单克隆抗体,该抗体可用于制备半夏凝集素蛋白检测试剂。
发明内容
解决的技术问题:为了定量检测样品中半夏凝集素蛋白含量,本发明提供半夏凝集素蛋白酶联免疫Elisa试剂盒及应用。
技术方案:半夏凝集素蛋白酶联免疫Elisa试剂盒,含有单克隆抗体25E2E8和/或单克隆抗体28E3D3。
上述25E2E8抗体的重链可变区的CDR-H1的氨基酸序列如SEQ ID NO:1所示,CDR-H2的氨基酸序列如SEQ ID NO:2所示,CDR-H3的氨基酸序列如SEQ ID NO:3所示;所述25E2E8抗体的轻链可变区的CDR-L1的氨基酸序列如SEQ ID NO:5所示,CDR-L2的氨基酸序列如SEQ ID NO:6所示,CDR-L3的氨基酸序列如SEQ ID NO:7所示。
上述25E2E8抗体重链的氨基酸序列如SEQ ID NO: 4所示,轻链的氨基酸序列如SEQ ID NO: 8所示。
编码所述单克隆抗体的核酸分子,所述25E2E8抗体重链的编码基因如SEQ ID NO:9所示;所述轻链的编码基因如SEQ ID NO:10所示。
上述28E3D3抗体的重链可变区的CDR-H1的氨基酸序列如SEQ ID NO:11所示,CDR-H2的氨基酸序列如SEQ ID NO:12所示,CDR-H3的氨基酸序列如SEQ ID NO:13所示;所述28E3D3抗体的轻链可变区的CDR-L1的氨基酸序列如SEQ ID NO:15所示,CDR-L2的氨基酸序列如SEQ ID NO:16所示,CDR-L3的氨基酸序列如SEQ ID NO:17所示。
上述28E3D3抗体重链的氨基酸序列如SEQ ID NO: 14所示,28E3D3抗体轻链的氨基酸序列如SEQ ID NO: 18所示。
编码所述单克隆抗体的核酸分子,所述28E3D3抗体重链的编码基因如SEQ ID NO:19所示;所述28E3D3抗体轻链的编码基因如SEQ ID NO:20所示。
上述单克隆抗体在制备半夏凝集素蛋白检测试剂中的应用。
有益效果:本发明提供一种用于检测半夏凝集素蛋白含量的试剂盒,是一种酶联免疫吸附测定试剂盒,由PTL的单克隆抗体制备而成,可以达到快速且灵敏地定量检测样品中PTL含量。
附图说明
图1纯化的单克隆抗体SDS-PAGE图;M. Marker;1. 28E3D3抗体;2. Mouse IgG;3.25E2E8抗体;4. Mouse IgG;
图2为25E2E8抗体Western Blot图;M. Marker;P.PTL;S. 半夏;
图3为28E3D3抗体Western Blot图;M. Marker;P.PTL;S. 半夏。
具体实施方式
以下结合附图和实验例对本发明的原理和特征进行描述,所举实施例只用于解释本发明,并非用于限定本发明的范围。下述实验例中的实验方法,如无特殊说明,均为常规方法。
实施例1: 单克隆抗体制备
(1)免疫原PTL的准备:称取适量半夏鲜品,洗净去皮后,加适量去离子水匀浆,8000 μg·mL-1离心30 min,取上清,加入饱和硫酸铵至45 %饱和度,搅拌均匀后8000 μg·mL-1离心20 min,收集沉淀,加适量0.6 mol·L-1硫酸铵溶液溶解,得到半夏蛋白粗提物。将粗提蛋白分别经疏水层析柱及离子交换柱层析纯化,经分子量为7000 Da的透析袋透析后冻干,得到纯化的半夏凝集素蛋白。
(2)动物免疫:将免疫原PTL溶于磷酸盐缓冲液(PBS,pH7.4)。将免疫原溶液与等体积弗氏完全佐剂进行充分乳化,在第0周进行初免,按照每只小鼠250 μg·mL-1 取进行腹腔注射免疫,免疫5只小鼠。分别在第2周、5周、8周按照每次125 μg·mL-1 的免疫原溶液与弗氏不完全佐剂的乳浊液进行加强免疫;第3周、7周、9周眼眶采血,10000 r·min-1离心5min,收集血清,采用间接ELISA方法进行血清效价测定(效价:为当待测孔A450值/阴性孔A450值≥2.1(P/N≥2.1)时的抗体最高稀释倍数),终免后5只小鼠的效价均达1:128000,进行下一步细胞融合。
(3)细胞融合及单抗制备:终免4天后用小鼠骨髓瘤细胞(S/P2)和免疫小鼠的脾细胞进行电融合,有限稀释法进行亚克隆,间接ELISA方法筛选特异性抗体,阳性细胞连续亚克隆培养,直至所有孔均为阳性为止,获得分泌单抗的细胞株,得到的细胞株经传代确定为稳定细胞株后,液氮保存。然后使用转瓶培养得到单克隆抗体,并采用Protein A亲和层析进行抗体纯化,通过透析将纯化抗体保存在磷酸盐缓冲液(PBS)中。
实施例2:单克隆抗体亚型的鉴定
使用小鼠抗体亚类鉴定试剂盒鉴定单克隆抗体亚型。
结果显示,本发明单克隆抗体为IgG1亚型鼠源单克隆抗体,轻链类型为κ。
实施例3:单克隆抗体纯度测定
采用SDS-PAGE法分析单克隆抗体纯度。
结果如图1所示,SDS-PAGE分析抗体纯度,在分子量约55kD和24kD处可见重链、轻链两个条带,抗体纯度较高。
实施例4:单克隆抗体的效价测定
采用间接ELISA 法测定抗体效价。采用本发明所述单克隆抗体25E2E8和28E3D3作为捕获抗体,包被酶标板,4℃过夜,使其吸附聚苯乙烯板孔,PBST洗涤1次后封闭2h;PTL从1000ng/mL倍比稀释,加入包被孔,100μL/孔,37℃孵育1h,PBST洗板4次;分别加入生物素标记的本发明所述单克隆抗体25E2E8、28E3D3,100μL/孔,37℃孵育1h,PBST洗板4次;加入SA-HRP,100μL/孔,37℃孵育15min,PBST洗板4次;加入TMB显色液显色15min后终止显色,读取OD450值,得到单抗腹水效价。
经检测,确定25E2E8、28E3D3的效价均达到1:512000。
实施例5:单克隆抗体特异性反应实验
为验证25E2E8、28E3D3是否特异结合PTL,将本发明所述单克隆抗体25E2E8、28E3D3作为一抗,通过Western blot法检测其特异反应。
经验证,25E2E8、28E3D3均可特异性地与PTL结合,在12kD左右出现特异性条带,说明抗原抗体特异性反应明显,结果如图2、图3所示。
以上所述仅是本发明地优选实施方式,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
序列表
<110> 南京中医药大学
<120> 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ser Ala Tyr Ala Trp Asn
1 5
<210> 2
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Tyr Ile Ser Phe Ser Gly Ser Thr Ser Tyr Ser Pro Ser Leu Lys Ser
1 5 10 15
<210> 3
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Asn Asn Phe Trp Tyr Phe Asp Val
1 5
<210> 4
<211> 459
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Arg Val Leu Ile Leu Leu Trp Leu Phe Thr Ala Phe Pro Gly Ile
1 5 10 15
Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro
20 25 30
Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ala Ile Thr
35 40 45
Ser Ala Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu
50 55 60
Glu Trp Met Gly Tyr Ile Ser Phe Ser Gly Ser Thr Ser Tyr Ser Pro
65 70 75 80
Ser Leu Lys Ser Arg Ile Ser Phe Thr Arg Asp Thr Ser Lys Asn Gln
85 90 95
Phe Phe Leu His Leu Asn Ser Val Thr Thr Asp Asp Thr Ala Thr Tyr
100 105 110
Tyr Cys Ala Arg Asn Asn Phe Trp Tyr Phe Asp Val Trp Gly Ala Gly
115 120 125
Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr
130 135 140
Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu
145 150 155 160
Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp
165 170 175
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
180 185 190
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser
195 200 205
Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser
210 215 220
Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys
225 230 235 240
Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro
245 250 255
Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr
260 265 270
Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser
275 280 285
Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg
290 295 300
Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile
305 310 315 320
Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn
325 330 335
Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys
340 345 350
Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu
355 360 365
Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe
370 375 380
Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala
385 390 395 400
Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr
405 410 415
Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly
420 425 430
Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His
435 440 445
Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
450 455
<210> 5
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu His
1 5 10 15
<210> 6
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Lys Val Ser Asn Arg Phe Ser
1 5
<210> 7
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ser Gln Ser Thr His Val Pro Pro Trp Thr
1 5 10
<210> 8
<211> 239
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
1 5 10 15
Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val
20 25 30
Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
35 40 45
Leu His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Gln Gln Lys Pro
50 55 60
Gly Gln Ser Pro Lys Leu Leu Ile Phe Lys Val Ser Asn Arg Phe Ser
65 70 75 80
Gly Val Pro Asp Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr
85 90 95
Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys
100 105 110
Ser Gln Ser Thr His Val Pro Pro Trp Thr Phe Gly Gly Gly Thr Arg
115 120 125
Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro
130 135 140
Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe
145 150 155 160
Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp
165 170 175
Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp
180 185 190
Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys
195 200 205
Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys
210 215 220
Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225 230 235
<210> 9
<211> 1380
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atgagagtgc tgattctttt gtggctgttc acagcctttc ctggtatcct gtctgatgtg 60
cagcttcagg agtcgggacc tggcctggtg aaaccttctc agtctctgtc cctcacctgc 120
actgtcactg gctacgcaat caccagtgct tatgcctgga attggatccg gcagtttcca 180
ggaaacaaac tggagtggat gggctacata agcttcagtg gtagtaccag ctactcccca 240
tctctcaaaa gtcgaatctc tttcactcga gacacatcca agaaccagtt cttcctgcac 300
ttgaattctg tgactactga cgacacagcc acatattact gtgcaaggaa taacttttgg 360
tacttcgatg tctggggcgc agggaccaca gtcaccgtct cctcagccaa aacgacaccc 420
ccatctgtct atccactggc ccctggatct gctgcccaaa ctaactccat gctgaccctg 480
ggatgcctgg tcaagggcta tttccctgag ccagtgacag tgacctggaa ctctggatcc 540
ctgtccagcg gtgtgcacac cttcccagct gtcctgcagt ctgacctcta cactctgagc 600
agctcagtga ctgtcccctc cagcacctgg cccagcgaga ccgtcacctg caacgttgcc 660
cacccggcca gcagcaccaa ggtggacaag aaaattgtgc ccagggattg tggttgtaag 720
ccttgcatat gtacagtccc agaagtatca tctgtcttca tcttcccccc aaagcccaag 780
gatgtgctca ccattactct gactcctaag gtcacgtgtg ttgtggtaga catcagcaag 840
gatgatcccg aggtccagtt cagctggttt gtagatgatg tggaggtgca cacagctcag 900
acgcaacccc gggaggagca gttcaacagc actttccgct cagtcagtga acttcccatc 960
atgcaccagg actggctcaa tggcaaggag ttcaaatgca gggtcaacag tgcagctttc 1020
cctgccccca tcgagaaaac catctccaaa accaaaggca gaccgaaggc tccacaggtg 1080
tacaccattc cacctcccaa ggagcagatg gccaaggata aagtcagtct gacctgcatg 1140
ataacagact tcttccctga agacattact gtggagtggc agtggaatgg gcagccagcg 1200
gagaactaca agaacactca gcccatcatg gacacagatg gctcttactt cgtctacagc 1260
aagctcaatg tgcagaagag caactgggag gcaggaaata ctttcacctg ctctgtgtta 1320
catgagggcc tgcacaacca ccatactgag aagagcctct cccactctcc tggtaaatga 1380
<210> 10
<211> 720
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat 60
gttgtgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc 120
tcttgcagat ctagtcagag ccttctacac agtaacggaa acacctattt acattggtac 180
cagcagaagc caggccagtc tccaaagctc ctgatcttca aagtttccaa ccgattttct 240
ggggtcccag acaggttcag tggcactgga tcagggacag atttcacact caagatcagc 300
agagtggagg ctgaggatct gggactttat ttctgctctc aaagtacaca tgttcctccg 360
tggacgttcg gtggaggcac caggctggaa atcaaacggg ctgatgctgc accaactgta 420
tccatcttcc caccatccag tgagcagtta acatctggag gtgcctcagt cgtgtgcttc 480
ttgaacaact tctaccccaa agacatcaat gtcaagtgga agattgatgg cagtgaacga 540
caaaatggcg tcctgaacag ttggactgat caggacagca aagacagcac ctacagcatg 600
agcagcaccc tcacgttgac caaggacgag tatgaacgac ataacagcta tacctgtgag 660
gccactcaca agacatcaac ttcacccatt gtcaagagct tcaacaggaa tgagtgttag 720
<210> 11
<211> 5
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Asn Tyr Trp Met Ser
1 5
<210> 12
<211> 19
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Glu Ile Arg Leu Lys Ser Ile Asn Tyr Ala Thr Leu Tyr Ala Glu Ser
1 5 10 15
Val Lys Gly
<210> 13
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Asn Arg Ser Phe Val Tyr
1 5
<210> 14
<211> 460
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Met Tyr Leu Gly Leu Asn Cys Val Phe Ile Val Phe Leu Leu Lys Gly
1 5 10 15
Val Gln Ser Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln
20 25 30
Pro Gly Gly Ser Met Lys Leu Ser Cys Ile Ala Ser Gly Phe Thr Phe
35 40 45
Ser Asn Tyr Trp Met Ser Trp Val Arg Gln Ser Pro Glu Lys Gly Leu
50 55 60
Glu Trp Val Ala Glu Ile Arg Leu Lys Ser Ile Asn Tyr Ala Thr Leu
65 70 75 80
Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser
85 90 95
Arg Ser Ser Val Phe Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr
100 105 110
Gly Ile Tyr Tyr Cys Ser Arg Asn Arg Ser Phe Val Tyr Trp Gly Gln
115 120 125
Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val
130 135 140
Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr
145 150 155 160
Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr
165 170 175
Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val
180 185 190
Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser
195 200 205
Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala
210 215 220
Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys
225 230 235 240
Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe
245 250 255
Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val
260 265 270
Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe
275 280 285
Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro
290 295 300
Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro
305 310 315 320
Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val
325 330 335
Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr
340 345 350
Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys
355 360 365
Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp
370 375 380
Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro
385 390 395 400
Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser
405 410 415
Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala
420 425 430
Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His
435 440 445
His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
450 455 460
<210> 15
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Arg Ser Ser Gln Ser Leu Leu Tyr Ser Ser Ile Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<210> 16
<211> 7
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Trp Ala Ser Thr Arg Glu Ser
1 5
<210> 17
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr
1 5
<210> 18
<211> 240
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Met Asp Ser Gln Ala Gln Val Leu Met Leu Leu Leu Leu Trp Ala Ser
1 5 10 15
Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Val
20 25 30
Val Ser Val Gly Glu Lys Ile Thr Met Ser Cys Arg Ser Ser Gln Ser
35 40 45
Leu Leu Tyr Ser Ser Ile Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln
50 55 60
Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65 70 75 80
Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
85 90 95
Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr
100 105 110
Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr
115 120 125
Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe
130 135 140
Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys
145 150 155 160
Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile
165 170 175
Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln
180 185 190
Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr
195 200 205
Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His
210 215 220
Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225 230 235 240
<210> 19
<211> 1383
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
atgtatttgg gactgaactg tgtattcata gtttttctct taaaaggtgt ccagagtgaa 60
gtgaagcttg aggagtctgg aggaggcttg gtgcaacctg gaggatccat gaaactctcc 120
tgtattgcct ctggattcac tttcagtaac tactggatga gctgggtccg ccagtctcca 180
gagaagggac ttgagtgggt tgctgaaatt agattgaaat ctattaatta tgcaacactt 240
tatgcggagt ctgtgaaagg gaggttcacc atttcaagag atgattccag aagtagtgtc 300
ttcctgcaaa tgaacaactt aagagctgaa gacactggca tttattactg ttccaggaat 360
cgatcctttg tttattgggg ccaggggact ctggtcactg tctctgcagc caaaacgaca 420
cccccatctg tctatccact ggcccctgga tctgctgccc aaactaactc catggtgacc 480
ctgggatgcc tggtcaaggg ctatttccct gagccagtga cagtgacctg gaactctgga 540
tccctgtcca gcggtgtgca caccttccca gctgtcctgc agtctgacct ctacactctg 600
agcagctcag tgactgtccc ctccagcacc tggcccagcg agaccgtcac ctgcaacgtt 660
gcccacccgg ccagcagcac caaggtggac aagaaaattg tgcccaggga ttgtggttgt 720
aagccttgca tatgtacagt cccagaagta tcatctgtct tcatcttccc cccaaagccc 780
aaggatgtgc tcaccattac tctgactcct aaggtcacgt gtgttgtggt agacatcagc 840
aaggatgatc ccgaggtcca gttcagctgg tttgtagatg atgtggaggt gcacacagct 900
cagacgcaac cccgggagga gcagttcaac agcactttcc gctcagtcag tgaacttccc 960
atcatgcacc aggactggct caatggcaag gagttcaaat gcagggtcaa cagtgcagct 1020
ttccctgccc ccatcgagaa aaccatctcc aaaaccaaag gcagaccgaa ggctccacag 1080
gtgtacacca ttccacctcc caaggagcag atggccaagg ataaagtcag tctgacctgc 1140
atgataacag acttcttccc tgaagacatt actgtggagt ggcagtggaa tgggcagcca 1200
gcggagaact acaagaacac tcagcccatc atggacacag atggctctta cttcgtctac 1260
agcaagctca atgtgcagaa gagcaactgg gaggcaggaa atactttcac ctgctctgtg 1320
ttacatgagg gcctgcacaa ccaccatact gagaagagcc tctcccactc tcctggtaaa 1380
tga 1383
<210> 20
<211> 723
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
atggattcac aggcccaggt tcttatgtta ctgctgctat gggcatctgg tacctgtggg 60
gacattgtga tgtcacagtc tccatcctcc ctagttgtgt cagttggaga gaaaattact 120
atgagctgca ggtccagtca gagcctttta tatagtagca ttcaaaagaa ctacttggcc 180
tggtaccagc agaaaccagg gcagtctcct aaactgctga tttactgggc atccactagg 240
gaatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 300
atcagcagtg tgaaggctga agacctggca gtttattact gtcagcaata ttatagctat 360
cctctcacgt tcggtgctgg gaccaagctg gagctgaaac gggctgatgc tgcaccaact 420
gtatccatct tcccaccatc cagtgagcag ttaacatctg gaggtgcctc agtcgtgtgc 480
ttcttgaaca acttctaccc caaagacatc aatgtcaagt ggaagattga tggcagtgaa 540
cgacaaaatg gcgtcctgaa cagttggact gatcaggaca gcaaagacag cacctacagc 600
atgagcagca ccctcacgtt gaccaaggac gagtatgaac gacataacag ctatacctgt 660
gaggccactc acaagacatc aacttcaccc attgtcaaga gcttcaacag gaatgagtgt 720
tag 723

Claims (7)

1.半夏凝集素蛋白酶联免疫Elisa试剂盒,其特征在于,含有单克隆抗体25E2E8或同时含有单克隆抗体25E2E8和单克隆抗体28E3D3,所述25E2E8抗体的重链可变区的CDR-H1的氨基酸序列如SEQ ID NO:1所示,CDR-H2的氨基酸序列如SEQ ID NO:2所示,CDR-H3的氨基酸序列如SEQ ID NO:3所示;所述25E2E8抗体的轻链可变区的CDR-L1的氨基酸序列如SEQ IDNO:5所示,CDR-L2的氨基酸序列如SEQ ID NO:6所示,CDR-L3的氨基酸序列如SEQ ID NO:7所示。
2.根据权利要求1所述的试剂盒,其特征在于,所述25E2E8抗体重链的氨基酸序列如SEQ ID NO: 4所示,轻链的氨基酸序列如SEQ ID NO: 8所示。
3.编码权利要求2中所述的单克隆抗体25E2E8的核酸分子,其特征在于:所述25E2E8抗体重链的编码基因如SEQ ID NO: 9所示;所述轻链的编码基因如SEQ ID NO:10所示。
4.根据权利要求1所述的试剂盒,其特征在于,所述28E3D3抗体的重链可变区的CDR-H1的氨基酸序列如SEQ ID NO:11所示,CDR-H2的氨基酸序列如SEQ ID NO:12所示,CDR-H3的氨基酸序列如SEQ ID NO:13所示;所述28E3D3抗体的轻链可变区的CDR-L1的氨基酸序列如SEQ ID NO:15所示,CDR-L2的氨基酸序列如SEQ ID NO:16所示,CDR-L3的氨基酸序列如SEQID NO:17所示。
5.根据权利要求1所述的试剂盒,其特征在于,所述28E3D3抗体重链的氨基酸序列如SEQ ID NO: 14所示,28E3D3抗体轻链的氨基酸序列如SEQ ID NO: 18所示。
6.编码权利要求5中所述的单克隆抗体28E3D3的核酸分子,其特征在于:所述28E3D3抗体重链的编码基因如SEQ ID NO: 19所示;所述28E3D3抗体轻链的编码基因如SEQ ID NO:20所示。
7.权利要求1中所述的单克隆抗体25E2E8在制备半夏凝集素蛋白检测试剂中的应用。
CN202210362218.6A 2022-04-07 2022-04-07 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用 Active CN114720689B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210362218.6A CN114720689B (zh) 2022-04-07 2022-04-07 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用
PCT/CN2022/109669 WO2023193376A1 (zh) 2022-04-07 2022-08-02 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210362218.6A CN114720689B (zh) 2022-04-07 2022-04-07 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用

Publications (2)

Publication Number Publication Date
CN114720689A CN114720689A (zh) 2022-07-08
CN114720689B true CN114720689B (zh) 2024-04-09

Family

ID=82242427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210362218.6A Active CN114720689B (zh) 2022-04-07 2022-04-07 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用

Country Status (2)

Country Link
CN (1) CN114720689B (zh)
WO (1) WO2023193376A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720689B (zh) * 2022-04-07 2024-04-09 南京中医药大学 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057989A1 (en) * 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
CN1300851A (zh) * 2000-12-22 2001-06-27 复旦大学 一种半夏凝集素蛋白及其编码序列
WO2007075915A2 (en) * 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
JP2009178156A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan クラスタリングによる蛋白質の有効性推定方法
CN102277328A (zh) * 2011-08-09 2011-12-14 华中农业大学 抗水稻白背飞虱的枯草芽胞杆菌工程菌及制备方法和应用
WO2015051320A2 (en) * 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
CN110468139A (zh) * 2018-05-09 2019-11-19 Fb遗传学(私人)有限公司 含四基因的盒库、重组dna分子及转基因棉花

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120034224A1 (en) * 2010-08-03 2012-02-09 National Cheng Kung University Treating Rheumatoid Arthritis with Anti-IL-19 Antibody
CN110684105B (zh) * 2019-09-11 2021-01-29 江苏莱森生物科技研究院有限公司 一种抗hsp90单克隆抗体及试剂盒
CN110927387B (zh) * 2019-11-08 2022-05-20 江苏大学 一种brca2蛋白酶联免疫双抗夹心试剂盒及其应用
CN110845610B (zh) * 2019-11-26 2021-06-15 武汉生物制品研究所有限责任公司 针对白喉类毒素的检测抗体对及其应用
CN114560938B (zh) * 2020-03-30 2023-05-23 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
CN114720689B (zh) * 2022-04-07 2024-04-09 南京中医药大学 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057989A1 (en) * 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
CN1300851A (zh) * 2000-12-22 2001-06-27 复旦大学 一种半夏凝集素蛋白及其编码序列
WO2007075915A2 (en) * 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
JP2009178156A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan クラスタリングによる蛋白質の有効性推定方法
CN102277328A (zh) * 2011-08-09 2011-12-14 华中农业大学 抗水稻白背飞虱的枯草芽胞杆菌工程菌及制备方法和应用
WO2015051320A2 (en) * 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
CN110468139A (zh) * 2018-05-09 2019-11-19 Fb遗传学(私人)有限公司 含四基因的盒库、重组dna分子及转基因棉花

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes;Hajime Wakui 等;《Chemical Science》;第11卷(第19期);全文 *
Generation of a recombinant chickenized monoclonal antibody against the neuraminidase of H9N2 avian influenza virus;Fei Wang 等;《AMB Express》;第10卷;全文 *
Non-covalent Assembly of Anti-Dendritic Cell Antibodies and Antigens for Evoking Immune Responses in vitro and in vivo;Anne-Laure Flamar 等;《Journal of immunology》;第189卷(第5期);全文 *
Pinellia pedatisecta Agglutinin Targets Drug Resistant K562/ADR Leukemia Cells through Binding with Sarcolemmal Membrane Associated Protein and Enhancing Macrophage Phagocytosis;Kan Chen 等;《PLOS ONE》;第8卷(第9期);全文 *
Radioimmunoassay of Pinellia ternata Lectin;JAE-ROK KIM 等;《The International Journal of Applied Radiation and Isotopes》;第36卷(第12期);全文 *
东北天南星凝集素基因的克隆及对蚜虫和褐飞虱的抗性研究;马宏宇;《中国优秀硕士学位论文全文数据库 农业科技辑》(第5期);全文 *
半夏凝集素基因的克隆、生物信息学分析及其蛋白的亚细胞定位;赵欢 等;《中草药》;第45卷(第13期);全文 *
法半夏炮制过程对半夏中毒蛋白凝集素蛋白的影响;李书晖 等;《中国中药杂志》;第45卷(第11期);全文 *

Also Published As

Publication number Publication date
WO2023193376A1 (zh) 2023-10-12
CN114720689A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
CN112250763B (zh) 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途
KR20130127998A (ko) 하이브리도머 세포주 10g4 및 그가 생성하는 항아플라톡신 b1, b2, g1, g2 총량 모노클론 항체
JP2010536886A5 (zh)
CN106916225B (zh) 一种检测n端脑钠肽前体的单克隆抗体及其杂交瘤细胞株和应用
US20160311895A1 (en) Antibody to n-terminal region of hemoglobin beta-chain
CN104862283B (zh) 一对高特异性高亲和力结合人肌红蛋白的单克隆抗体及其应用
CN114181308B (zh) 一种降钙素原抗体及其应用
CN114720689B (zh) 半夏凝集素蛋白酶联免疫Elisa试剂盒及应用
CN113004412B (zh) 胃蛋白酶原i单克隆抗体及其应用
CN116375856A (zh) 一种抗Tau蛋白的单克隆抗体1A5-47H7和基于其的产品以及应用
CN106814192B (zh) 用于肝癌检测的标志物组合及检测试剂盒
CN116284382A (zh) 抗降钙素原抗体及其应用
WO2023277143A1 (ja) SARS-CoV-2のヌクレオカプシドタンパク質に対する抗体及びその用途
CN109575133B (zh) 抗人β2-MG抗体及其应用
CN109725159B (zh) 人β2-微球蛋白的定量检测试纸卡与临床应用
CN109666072B (zh) 抗人β2-微球蛋白抗体及其应用
CN108004214B (zh) Homer2单克隆抗体及其应用
KR20180091930A (ko) Cgrp 항체 및 그의 용도
CN104830805B (zh) 抗人翻译控制肿瘤蛋白单克隆抗体杂交瘤及其单克隆抗体与应用
KR20200099421A (ko) 대칭적 디메틸아르기닌과 특이적으로 결합하는 항체 및 이의 용도
CN110724671A (zh) 杂交瘤细胞株1g8、抗体及其应用
CN110579610A (zh) 用于检测t细胞活化的v域免疫抑制因子的试剂盒
CN116284411B (zh) 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
US20110281284A1 (en) Novel liver cancer marker
CN114195891B (zh) 一种crp驼源单域抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant